While the developments of the approaches targeting the DM1 mutations and the mutant DMPK mRNA using AONs are in progress, DM1 pathology could be corrected via normalization of RNA-binding proteins, CUGBP1 and MBNL1. This evidence concerns the gene CELF1 and myotonic dystrophy type 1.